Ornizol solution for infusions 5 mg/ml. 100 ml. vial

Description

Ornizol composition
The main active ingredient: ornidazole.
Excipients: sodium chloride, water for injection.
1 ml of the drug contains 5 mg of ornidazole.

Release form
The drug is produced in the form of an infusion solution, in bottles of 100 ml of ornidazole.

Pharmacological properties
This Ornizol drug belongs to the group of antibacterial drugs used systemically.
The main component, ornidazole, is an imidazole derivative, an antibiotic that is similar in properties to metronidazole and other 5-nitroimidazoles.
Shows antibacterial and antiprotozoal effect against Trichomonas, lamblia, gardnerella, and other microorganisms, including anaerobic cocci.
In terms of the mechanism of its action, this substance is similar to DNA-tropic pharmaceuticals, since it has a selective effect on microorganisms that have enzyme systems.
After this component enters the cell of a pathogenic microorganism, due to a number of metabolic processes, it leads to the cell’s DNA degradation, which causes a violation of its replication (reproduction and reproduction) and transcription (transfer of elements) DNA.
Also, as a result of the metabolic processes that this substance causes in the cells, toxins are released that cause impaired cell respiration, which also leads to the death of pathogen cells.

Indications
This medicinal product Ornizol is intended for the treatment of anaerobic systemic infections caused by microflora sensitive to ornidazole. In particular, for treatment:

• septiceia;
• meningitis, peritonitis;
• postoperative wound infections;
• postpartum sepsis;
• septic abortion;
• endometritis;
• severe amoebic dysentery;
• all extraintestinal forms of amebiasis, giardiasis;
• liver abscess.

It is also used to prevent the development of infections caused by anaerobic bacteria, which can develop as a result of surgical intervention (especially during operations on the colon and rectum), during gynecological operations.

Contraindications
The drug in question is not used if the patient has ever had hypersensitivity (allergy) to one of the components that make up its composition.
Also contraindicated for use with:

• organic diseases of the central nervous system;
• epilepsy;
• multiple sclerosis;
• circulatory disorders;
• chronic alcoholism.

Caution should be exercised when treating patients suffering from:

• liver failure;
• brain damage;
• disorders of hematopoiesis.

Children
In pediatrics, it is used to treat children over the age of 1 year and who have gained weight over 6 kg.

Application during pregnancy and lactation
This drug is contraindicated for the treatment of pregnant women in the first trimester of pregnancy. During the II and III trimesters, it is permissible to prescribe only for serious indications.
Lactation is suspended for the duration of treatment with this drug.

Method of administration and dosage
The exact dosage is determined by the attending physician.
Recommended use:

• for children under 12 years of age – the daily dose is calculated at the rate of 20 mg per 1 kg of the patient’s body weight, administered in 2 procedures per day, the duration of treatment is 5-10 days;
• for children over 12 years of age and for adults, the initial dose is 500 mg – 1 gram for the first administration. Then, every 12 hours, 500 mg or 1 gram is administered every 24 hours, the duration of treatment is 5-10 days.

To prevent the development of infections after surgical abdominal operations, 500 mg – 1 gram is administered 30 minutes before the operation.
The maintenance dosage can be taken in tablet form, 1 tablet of 500 mg every 12 hours.
If there is a need to use this drug in the treatment of mixed infections, it is permissible to take it simultaneously with drugs-aminoglycosides, penicillins or drugs of the cephalosporin group. However, mixing of drugs for injection in 1 bottle is not allowed.
For amoebiasis, giardiasis, a dosage similar to the usual systemic treatment is recommended, but the duration of treatment is reduced to 3-6 days.
In case of hepatic insufficiency, it is recommended to reduce the dosage or lengthen the interval of administration.

Overdose
An overdose of this drug can cause:

• loss of consciousness;
• headache;
• dizziness;
• tremor, trembling of the limbs;
• convulsions;
• depression, peripheral neuritis;
• nausea, vomiting.

Symptomatic therapy is recommended.

Side effects
The use of this drug in a patient can cause side effects in the form of:

• metallic taste in the mouth;
• nausea, loss of appetite;
• epigastric pain;
• vomiting;
• headache, dizziness, tremor, impaired coordination of movements;
• ataxia, seizures, confusion;
• signs of sensory or mixed peripheral neuropathy;
• allergic reactions (itching, rash, allergic urticaria, angioedema);
• moderate leukopenia, darkening of urine;
• cardiovascular disorders.

Storage conditions and periods
This Ornizol medicinal product retains its medicinal properties for 2 years, which are counted from the date of manufacture, which is indicated by the manufacturer.
The drug should be kept out of the reach of children. Storage temperature should not exceed 25 ° C.